Xcopri, SK Biopharmaceutical's new epilepsy drug, is continuing to show strong growth in the US market. Since its launch, sales have continued to rise every quarter, with cumulative sales exceeding KRW 600 billion. When including the revenue it had collected by licensing-out Xcopri’s technology, the company has secured more than KRW 1 trillion with Xcopri alone.

According to SK Biopharmaceuticals on Thursday, Xcopri recorded KRW 90.9 billion in US sales in Q1 this year. This is a 68.6% rise from the KRW 53.9 billion it had posted in Q1 last year and is the largest amount earned since the drug entered the US market. This is also a 17.0% increase in a single quarter, from the KRW 77.7 billion in Q4 last yea